Phenylpropanolamine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Phenylpropanolamine
- Phenylpropanolamine: From an Unrecorded Original Indication to Nasal Cavity Disease
Phenylpropanolamine: From an Unrecorded Original Indication to Nasal Cavity Disease
One-Sentence Summary
Phenylpropanolamine’s original approved indication and mechanism of action are not yet recorded in this evidence pack. The TxGNN model predicts it may be effective for Nasal Cavity Disease, but currently no clinical trials and no publications support this direction — the signal comes from the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not currently on record |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.98% (rank 245) |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available, and no original indication is on record for phenylpropanolamine in this evidence pack. As a result, the pharmacological rationale linking any prior use to the predicted new indication cannot be independently assessed at this time.
The prediction is based solely on the TxGNN knowledge graph’s network-level association between phenylpropanolamine and nasal cavity disease (score 99.98%, ranked 245th among all candidate disease associations for this drug). A high model score can reflect genuine biological signal, but without corroborating mechanism-of-action or clinical evidence, it should be treated as a hypothesis-generating result rather than a validated pharmacological rationale.
Four additional lower-confidence predictions were also generated (acute laryngopharyngitis, rosacea conjunctivitis, faucial diphtheria, cervical disc degenerative disorder), none of which are supported by clinical trials or literature either — reinforcing that this candidate is still at the earliest stage of the repurposing pipeline.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Phenylpropanolamine is not currently registered in South Africa — no SAHPRA registration records are available (0 licenses on file).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication is supported only by a model score (L5), with no clinical trials, literature, mechanism-of-action data, or South African market presence to corroborate it. A blocking safety data gap (no PI/warnings on file) also prevents any preliminary safety assessment.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI), including warnings, contraindications and drug interactions — currently blocking
- Confirmed mechanism of action (MOA) data from DrugBank
- Confirmation of the drug’s original approved indication(s)
- Independent clinical or preclinical evidence connecting phenylpropanolamine to nasal cavity disease before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.